![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
METABOLISM, TRANSPORT, AND PHARMACOGENOMICS
School of Pharmacy (E.M.L., K.L.R.B.) and School of Medicine (P.B.W.), University of North Carolina, Chapel Hill, North Carolina; and Division of Clinical Pharmacology, Departments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee (R.B.K.)
Received December 23, 2006; accepted March 19, 2007.
 |
Abstract |
|---|
 Top Abstract Materials and MethodsResultsDiscussionReferences |
|---|
). In the preapproval clinical trials, 
11% of patients treated with bosentan developed hepatotoxicity, as reflected by elevations in serum transaminases exceeding three times the upper limits of normal (Cohen et al., 2004; Williams et al., 2006). In a few patients with multiple comorbidities and multiple drug therapies, cases of severe hepatotoxicity were reported, in which the contribution of bosentan could not be excluded (Sitbon et al., 2005). As a result, it is recommended that all bosentan-treated patients undergo frequent biochemical monitoring of liver enzymes. Moreover, the potential for hepatotoxicity needs to be taken into consideration in patients with predisposing factors, such as liver fibrosis. Nevertheless, with monitoring, the risk/benefit ratio remains clearly favorable for bosentan, since first-line bosentan treatment is associated with increased survival of patients with pulmonary arterial hypertension (Sitbon et al., 2005; Williams et al., 2006). Overall, there has been considerable interest in determining the mechanisms that underlie bosentan-induced hepatotoxicity.
Although most postulated mechanisms for drug induced liver injury involve production of reactive metabolites (Park et al., 2005), it has been proposed that bosentan-induced liver injury is due to accumulation of bile acids in the hepatocyte resulting from inhibition of the canalicular bile salt export pump (BSEP/ABCB11) (Fattinger et al., 2001). This mechanism is consistent with the observation that human BSEP is inhibited by bosentan in vitro, that the incidence of liver injury is related to dose, and that mild liver injury frequently reverses with a reduction in daily dosing (Noé et al., 2002; Segal et al., 2005; Mano et al., 2007). Inhibition of BSEP as a mechanism for hepatotoxicity also is consistent with the reported observations that serum bile acids were increased before development of hepatotoxicity in patients in the bosentan clinical trials (Fattinger et al., 2001) and that bosentan hepatotoxicity was more common in patients also treated with glyburide, a known BSEP inhibitor (Stieger et al., 2000; Fattinger et al., 2001).
Bosentan administered intravenously to rats increased serum bile acids presumably through inhibition of Bsep which has been observed in vitro (Fattinger et al., 2001), suggesting that the rat might be a good model to study bosentan hepatotoxicity. However, bosentan-treated rats do not develop hepatotoxicity (Fattinger et al., 2001). This finding suggests that either BSEP inhibition is not a mechanism underlying bosentan hepatotoxicity or that factors mitigate the impact of BSEP inhibition in the rat but not in human. Fattinger et al. (2001) proposed that rats may be less susceptible to bosentan-induced hepatotoxicity because rat bile acids are inherently less toxic than human bile acids. Indeed, rat bile acid composition is more hydrophilic and therefore, generally less toxic than the human bile acid pool to both hepatocytes and erythrocytes (Coleman et al., 1979); however, taurocholic acid and taurochenodeoxycholic acid, which make up 81% of the rat bile acid pool (Alvaro et al., 1986), are capable of eliciting hepatotoxicity (Crocenzi et al., 1997; Sokol et al., 1998). Thus, another potential explanation was provided by the recent observation that bosentan inhibits Na+-dependent taurocholate uptake in rat hepatocytes (Kemp et al., 2005). The Na+-dependent taurocholate cotransporting polypeptide (Ntcp/Slc10a1) is the only Na+-dependent bile acid transporter in hepatocytes and is responsible for the majority of bile acid uptake from sinusoidal blood (Geyer et al., 2006). Bosentan inhibition of Ntcp-mediated bile acid uptake could counterbalance Bsep inhibition, reduce intrahepatocyte bile acid accumulation, and thereby prevent hepatotoxicity in the rat. Preferential inhibition by bosentan of rat Ntcp versus human NTCP would therefore provide a potential explanation for the rat resistance to bosentan-induced hepatotoxicity.
Species differences in inhibition of Ntcp/NTCP by bosentan is plausible because disparities between rat and human Ntcp/NTCP substrate specificities have been observed, including a difference in affinity for taurocholate uptake by Ntcp (Km 25 µM) and NTCP (Km 6 µM) (Hagenbuch et al., 1991; Hagenbuch and Meier, 1994). Moreover, Ho et al. (2006) recently reported that rosuvastatin is a substrate for NTCP but not for Ntcp.
In the current study, the hypothesis that bosentan is a more potent inhibitor of rat Ntcp than human NTCP was tested using suspended hepatocytes and expressed recombinant native and chimeric transporters. Our data support this hypothesis and suggest a novel mechanism for species differences in hepatotoxicity.
|
Materials and Methods |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Antibodies and Cell Lines. Rabbit pAb anti-calreticulin antibody was purchased from Novus Biologicals, Inc. (Littleton, CO), mouse anti-V5 antibody was purchased from Invitrogen, and mouse anti-
-actin antibody C4 was purchased from Chemicon International (Temecula, CA). The SV40-transformed human embryonic kidney (HEK293) cell line was maintained in DMEM with 4 mM L-glutamine and 10% fetal bovine serum.
Human Hepatocyte Isolation and Culture. The demographics of liver tissue donors are summarized in Table 1. Hu274 and Hu299 were obtained from CellzDirect (Pittsboro, NC). Livers 1 to 3 were isolated from human liver tissue procured through the Department of Surgery, University of North Carolina at Chapel Hill School of Medicine (Chapel Hill, NC) by a modification of the two-step collagenase digestion method (Hamilton et al., 2001). All human liver tissue was obtained from fresh resections by qualified medical staff, with donor consent and with the approval of the University of North Carolina Hospitals Ethics Committee. Hepatocytes were cultured according to the methods described by Hoffmaster et al. (2004) with modifications. Hepatocytes were seeded at 1.5 x 106 cells/well on six-well Biocoat culture plates in 1.5 ml of phenol red-free DMEM supplemented with 5% fetal bovine serum, 0.1 mM modified essential medium nonessential amino acids, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 4 µg/ml human recombinant insulin, and 1 µM dexamethasone and allowed to attach for 2 to 6 h at 37°C in a humidified incubator with 95% air/5% CO2. After cell attachment, culture dishes were gently swirled, and medium was replaced with phenol red-free DMEM supplemented as above except with 0.1 µM dexamethasone, 6.25 µg/ml insulin, 6.25 µg/ml transferrin, and 6.25 ng/ml selenium (ITS+). Cells were overlaid 6 to 12 h postseeding with 0.25 mg/ml Matrigel in 1.5 ml of ice-cold medium. Cultures were maintained with daily media changes for 6 days before use in experiments.
|
Sandwich-Cultured Human Hepatocyte Transport Studies. Methods to determine the accumulation and the in vitro biliary clearance (CLbile) in sandwich-cultured (SC) hepatocytes have been described previously (Liu et al., 1999; Annaert and Brouwer, 2005). Briefly, human hepatocytes were rinsed twice with 2 ml of warm standard HBSS or Ca2+-free HBSS with EGTA (1 mM) and preincubated with 2 ml of the same buffer for 10 min at 37°C. The medium was removed, and SC hepatocytes were incubated for 10 min with [3H]taurocholate (1 µM; 100 nCi) in 1 ml of standard HBSS in the presence of bosentan (0–100 µM). After incubation, dishes were washed vigorously 3 times with 2 ml of ice-cold HBSS. Hepatocytes were lysed with 1 ml of 0.5% Triton X-100, and 500 µl was analyzed by liquid scintillation counting. Data were normalized to the protein content of the hepatocytes using a BCA protein assay.
The in vitro biliary clearance (in vitro CLbile in microliters per minute per milligram of protein) of taurocholate was calculated using B-CLEAR technology (Qualyst, Inc., Raleigh, NC) based on the following equation:
 |
Animals. Male Wistar rats (220–300 g) (Charles River Laboratories, Inc., Raleigh, NC) were used as liver donors for hepatocyte isolation. Rats were maintained on a 12-h light/12-h dark cycle with free access to water and rodent chow. Rats were allowed to acclimate for at least 5 days before experimentation. The Institutional Animal Care and Use Committee of the University of North Carolina at Chapel Hill approved all procedures.
Transport Studies Using Suspended Primary Rat and Human Hepatocytes. Rat hepatocytes were isolated from male Wistar rats by a two-step collagenase perfusion method as described previously (Liu et al., 1999). Human hepatocytes were isolated in a similar manner, as described above. Isolated hepatocytes were washed twice with cold HBSS modified with 10 mM Tris and 5 mM glucose (+ Na+ condition) or Na+-free choline buffer (10 mM Tris, 5 mM glucose, 5.4 mM KCl, 1.8 mM CaCl2, 0.9 mM MgSO4, 10 mM HEPES, and 137 mM choline). Cells were suspended at 1 x 106 cells/ml in the same buffer, placed on ice, and used immediately in experiments. Hepatocyte suspensions (4 ml for rat; 1 ml for human) were preincubated at 37°C for 5 min in bottom inverted Erlenmeyer flasks (rat) or for 3 min in 16 x 100 mm test tubes (human); vehicle or bosentan (0.1–100 µM) was added followed by [3H]taurocholate (1 µM; 60 nCi/ml). At 30 s (rat) and 45 s (human), 200-µl samples were removed, placed in a 0.4-ml polyethylene tube containing a top layer of silicone oil:mineral oil (82:18, v/v) (100 µl) and a bottom layer of 3 M KOH (50 µl) and centrifuged. Radioactivity in the cell pellet and supernatant was quantified by liquid scintillation counting. The adherent fluid volume was determined by incubation of cells with [14C]inulin. Protein concentrations in the incubation mixtures were quantitated at the end of each experiment.
Construction of Vectors Encoding Ntcp/NTCP Hybrid Proteins. The full open reading frames of NTCP and Ntcp cDNAs were obtained by PCR, using AmpliTaq DNA polymerase (PerkinElmer Life and Analytical Sciences), from cDNA libraries synthesized from human and rat liver mRNA, respectively, as described previously (Tirona et al., 2003). NTCP and Ntcp cDNAs were cloned using TOPO TA cloning technology into pEF6/V5-His (pEF6-NTCP and pEF6-Ntcp, respectively) and Ntcp also was cloned into pCR2.1 (pCR2.1-Ntcp) with primers that removed the stop codon and left the V5 tag intact. Ntcp1–140/NTCP141–349 was generated by PCR amplification of the first 414 nucleotides of Ntcp from pCR2.1-Ntcp using a 5' primer complementary to the pCR2.1 vector, 38 nucleotides before the start of the Ntcp ORF 5'-... gctcggatccagtgtgatggatatctgcag...-3' with an engineered BamHI site (italics) and a 3' primer complementary to nucleotides 392 to 411 in Ntcp,... tagatgtacaagaggagtggcatcatgccca... 3' with an engineered BsrGI site (italics). The PCR product and the pEF6-NTCP vector [construction described previously (Ho et al., 2004)] were then digested with BamHI and BsrGI and then ligated together replacing the first 414 nucleotides of NTCP with the first 414 nucleotides of Ntcp.
The NTCP1–140/Ntcp141–362 was generated by PCR amplification of nucleotides 414 to 1086 of rat Ntcp from pEF6-Ntcp using a 5' primer complementary to nucleotides 419 to 438 in Ntcp, 5'... atcttgtacatctacagcaaaggcatctac... 3', with an engineered BsrGI site (italics) and a3' primer complementary to the BGH reverse priming site in the pEF6/V5-His vector, 5'.... cctcgactgtgccttcta.... 3'. The PCR product and the pEF6-NTCP vector were digested with BsrGI and NotI and then ligated together, replacing the first 414 nucleotides of Ntcp with the first 414 nucleotides of NTCP.
Expression and Functional Characterization of NTCP, Ntcp, NTCP1–140/Ntcp141–362, and Ntcp1–140/NTCP141–349 in HEK293 Cells. The wild-type and hybrid NTCP and Ntcp constructs were transiently transfected into HEK293 cells using FuGENE6 according to the manufacturer's instructions. Briefly, cells were seeded at 3 x 106 cells in a T-75 flask, and 24 h later, 7.8 µg of DNA and 23 µl of FuGENE 6 (1:3 DNA-FuGENE 6) were combined in serum-free media and added to each flask. When confluent (60–72 h later), cells were trypsinized, washed twice with HBSS, and suspended at 4 x 106 cells/ml of HBSS. Uptake experiments were conducted as described above for suspended primary human hepatocytes. In addition, at the end of each experiment approximately 4 x 106 cells were retained for immunoblot analysis. Immunoblots of NTCP, Ntcp, NTCP1–140/Ntcp141–362, and Ntcp1–140/NTCP141–349 were performed using the mouse anti-V5 antibody diluted at 1:5000. Membranes were stripped and blotted with the mouse anti--actin antibody diluted at 1:5000, and protein loading was normalized by densitometry. The functional activities of Ntcp, NTCP, NTCP1–140/Ntcp141–362, and Ntcp1–140/NTCP141–349 reported throughout the manuscript were normalized for protein expression levels.
Total and Cell Surface Expression of NTCP, Ntcp, NTCP1–140/Ntcp141–362, and Ntcp1–140/NTCP141–349. HEK293 cells were grown on six-well plates and transfected as described above. Biotinylation experiments were conducted 48 to 72 h post-transfection as described previously (Ho et al., 2004), with modifications. Cells were washed with ice-cold phosphate-buffered saline (PBS) and then treated with sulfo-N-hydroxysuccinimide-SS-biotin (1.5 mg/ml in PBS) for 1 h at 4°C. Cells were washed three times with PBS containing 100 mM glycine and incubated for 20 min at 4°C with the same buffer. Cells were washed with PBS, scraped into 1 ml of phosphate-buffered saline, and pelleted by centrifugation at 800g for 2 min. The pellet was treated with 700 µl of lysis buffer (10 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, and 1% Triton X-100, pH 7.4, with protease inhibitors) for 1 h at 4°C with shaking. Cell lysates were spun at 16,000g for 10 min, the supernatant was retained, and protein concentrations were determined using a BCA kit. Lysates were diluted to equivalent protein concentrations (0.1 µg/µl) by adding additional lysis buffer, and 600 µl was incubated with 140 µl of streptavidin-agarose beads for 1 h at 25°C with constant agitation. Beads were pelleted at 5000g and washed 4 times with ice-cold lysis buffer. The beads were resuspended in 50 µl of 4xLaemmli buffer and incubated at 70°C for 20 min, and 25 µl was subjected to SDS-polyacrylamide gel electrophoresis and immunoblot analysis along with 12.5 µl (1.25 µg of protein) of total cell lysate. NTCP, Ntcp, and chimeric proteins were detected with the mouse anti-V5 antibody diluted 1:5000. Blots were stripped and to ensure that the biotinylation was specific to cell surface proteins, the endoplasmic reticulum-specific protein calreticulin was detected using rabbit pAb anti-calreticulin diluted at 1:1000. Protein loading was normalized using the mouse anti--actin antibody diluted at 1:5000.
|
Results |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
). Thus, SC hepatocytes are a valid and increasingly popular model to study transport processes responsible for basolateral uptake and biliary excretion (Liu et al., 1999; Ghibellini et al., 2006). The effect of bosentan on taurocholate accumulation in SC human hepatocytes was determined at a 10-min time point (Fig. 1). The accumulation of taurocholate in cells + canalicular networks (Ca2+-containing condition) was inhibited in a concentration-dependent manner by bosentan and was reduced significantly by 
30 µM bosentan (Fig. 1A). Inhibition of taurocholate accumulation in cells alone (Ca2+-free conditions) also occurred in a concentration-dependent manner and was significantly reduced at bosentan concentrations of 10 µM (Fig. 1A). Calculation of the mean in vitro CLbile showed a concentration-dependent inhibition of taurocholate biliary clearance at 30 µM bosentan (Fig. 1B).
|
; Shitara et al., 2003), and Na+-dependent uptake was the predominant mechanism of taurocholate uptake by both rat and human hepatocytes (Shitara et al., 2003). Na+-dependent uptake accounted for 68 and 97% of taurocholate uptake by rat and human hepatocytes, respectively. Bosentan was 6-fold more potent as an inhibitor of initial rates of Na+-dependent taurocholate uptake in rat than in human hepatocytes (IC50 5.4 µM versus 30 µM, respectively) (Fig. 2; Table 2)
|
|
Bosentan Was a More Potent Inhibitor of Ntcp Than NTCP Transiently Expressed in HEK293 Cells. To confirm the finding that bosentan inhibits Na+-dependent taurocholate uptake more potently in rat than in human hepatocytes and to further characterize species differences, NTCP and Ntcp were transiently expressed in HEK293 cells, and taurocholate transport was measured in the presence and absence of bosentan. Consistent with previous reports (Hagenbuch and Meier, 1994), the rate of taurocholate uptake by rat Ntcp was lower than that by human NTCP (Fig. 3A). Consistent with observations in suspended primary rat and human hepatocytes, bosentan was a more potent inhibitor of rat Ntcp (IC50 0.7 µM) than human NTCP (IC50 24 µM) (Fig. 3B; Table 2) expressed in HEK293 cells.
|
45 kDa for rat Ntcp and NTCP1–140/Ntcp141–362 and 43 kDa for human NTCP and Ntcp1–140/NTCP141–349. Expression levels of NTCP and Ntcp1–140/NTCP141–349 were consistently lower than those for Ntcp and NTCP1–140/Ntcp141–362 for both total and cell surface protein (Fig. 5, A, top, and B). Cell surface biotinylation experiments indicated that all four proteins were expressed at the cell membrane, and levels at the cell surface were proportional to total protein levels (Fig. 5, A and B). Calreticulin, an endoplasmic reticulum-specific protein, was detected in the total protein but not the cell surface fraction (Fig. 5A, middle), indicating that the biotinylation method successfully enriched the fraction for proteins expressed at the cell surface.
|
|
Uptake of Taurocholate by NTCP, Ntcp, NTCP1–140/Ntcp141–362, and Ntcp1–140/NTCP141–349. As a preliminary characterization of chimera function, a time course of taurocholate (1 µM, 60 nCi) uptake by HEK293 cells expressing NTCP, Ntcp, NTCP1–140/Ntcp141–362, or Ntcp1–140/NTCP141–349 was measured (Fig. 6A). Compared with the untransfected control, significant taurocholate uptake in the linear range was observed for all proteins from 30 to 180 s. Activities at 180 s for untransfected HEK293 cells and cells expressing NTCP, Ntcp, NTCP1–140/Ntcp141–362, and Ntcp1–140/NTCP141–349 were 2.95, 514, 211, 207, and 522 pmol/mg/min, respectively. Interestingly, the activity of taurocholate uptake appeared to be dictated by the carboxyl half of the protein with the Ntcp1–140/NTCP141–349 chimera having activity similar to that of NTCP and the NTCP1–140/Ntcp141–362 chimera having activity similar to that of Ntcp.
|
Kinetics of Taurocholate Uptake by NTCP, Ntcp, NTCP1–140/Ntcp141–362, and Ntcp1–140/NTCP141–349. Uptake of taurocholate by NTCP, Ntcp, NTCP1–140/Ntcp141–362, and Ntcp1–140/NTCP141–349 was characterized further by determining the initial rates of uptake over several concentrations of taurocholate (Fig. 6B; Table 2). Kinetic parameters determined for NTCP (apparent Km 2.1 µM and Vmax 814 pmol/mg/min) and Ntcp (apparent Km 2.6 µM and Vmax 357 pmol/mg/min) suggested that the difference in taurocholate transport activity for NTCP and Ntcp was due to a difference in Vmax. This result contrasted with previous reports suggesting that the apparent Km was 4-fold higher for rat Ntcp compared with human NTCP (Hagenbuch et al., 1991; Hagenbuch and Meier, 1994).
Consistent with the time course (Fig. 6A), the kinetic parameters determined for NTCP1–140/Ntcp141–362 (apparent Km 3.5 µM and Vmax 420 pmol/mg/min) were similar to those for Ntcp. In addition, kinetic parameters determined for Ntcp1–140/NTCP141–349 (apparent Km 4.1 µM and Vmax 713 pmol/mg/min) were similar to those for NTCP. No significant difference existed between the apparent Km values determined for the four proteins.
Bosentan Inhibition of NTCP, Ntcp, NTCP1–140/Ntcp141–362, and Ntcp1–140/NTCP141–349. The ability of bosentan to inhibit taurocholate uptake by HEK293 cells expressing NTCP1–140/Ntcp141–362 and Ntcp1–140/NTCP141–349 was evaluated and compared with that for NTCP and Ntcp (Fig. 7). Consistent with previous experiments, taurocholate uptake by Ntcp- and NTCP1–140/Ntcp141–362-expressing cells was lower than that by NTCP and Ntcp1–140/NTCP141–349 (Fig. 7). Somewhat unexpectedly, the difference between bosentan inhibition of taurocholate uptake for NTCP1–140/Ntcp141–362 (IC50 3.0 µM) and Ntcp1–140/NTCP141–349 (IC50 2.4 µM) was not statistically significant (Fig. 7; Table 2).
|
The inhibition of taurocholate transport was further characterized for NTCP, Ntcp, and chimeric proteins by measuring the effect of two different concentrations of bosentan on the initial rates of taurocholate (0.6–30 µM) uptake (Fig. 8). Bosentan behaved as a competitive inhibitor of human NTCP with an apparent Ki of 18 µM (Fig. 8A; Table 2). In contrast, bosentan inhibited rat Ntcp in a noncompetitive manner (Fig. 8B). The Vmax for taurocholate transport by Ntcp was decreased from 408 pmol/mg/min in the absence of bosentan to 225 pmol/mg/min in the presence of 0.3 µM bosentan, whereas there was no significant effect on the apparent Km. Inhibition of Ntcp1–140/NTCP141–349 was a mixture of competitive and noncompetitive inhibition with a decrease in both the apparent Km and Vmax; the apparent Ki was 7 µM, and the Vmax was decreased from 615 to 395 pmol/mg/min in the presence of 10 µM bosentan (Fig. 8C). Bosentan was a competitive inhibitor of taurocholate uptake by NTCP1–140/Ntcp141–362 with a Ki value of 1.7 µM (Fig. 8D).
|
|
Discussion |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
; Noé et al., 2002; Mano et al., 2007). Bosentan also inhibits Na+-dependent taurocholate uptake by rat hepatocytes (Kemp et al., 2005). This result suggests that hepatoxicity may reflect the balance between bosentan inhibition of bile acid efflux versus uptake. Thus, preferential inhibition of rat Ntcp versus human NTCP could explain why the rat is resistant to bosentan-induced hepatotoxicity.
In SC human hepatocytes, the biliary clearance of taurocholate was inhibited by bosentan in a concentration-dependent manner. This result is consistent with what has previously been reported in SC rat hepatocytes treated with bosentan (Kemp et al., 2005) and supports simultaneous inhibition of both NTCP and BSEP. We next tested the hypothesis that rat Ntcp would be more sensitive to inhibition than human NTCP. The initial rate of Na+-dependent taurocholate uptake was inhibited by bosentan 6-fold more potently in rat hepatocytes than in human hepatocytes. Bosentan also was a more potent inhibitor of rat Ntcp than human NTCP expressed in HEK293 cells.
Because inhibition of NTCP/Ntcp may offset the effect of BSEP inhibition by preventing the uptake of bile salts from blood and the subsequent accumulation within the hepatocyte, the more potent inhibition of Ntcp than NTCP by bosentan provides a plausible mechanism for protection of the rat from bosentan hepatotoxicity. At the therapeutically relevant unbound plasma concentrations of bosentan in patients (Cmax 2 µM, 98% protein-bound) (Weber et al., 1999), no significant inhibition in bile acid uptake by human NTCP would be expected. Thus, differential inhibition of bile acid uptake and efflux could account for differences between rats and humans in susceptibility to bosentan-induced hepatotoxicity.
Kinetic parameters of taurocholate transport by NTCP and Ntcp were determined and revealed a 2.3-fold higher Vmax for human protein than for rat protein but virtually identical apparent Km values (Table 2). The addition of the V5 epitope tag on the proteins allowed the normalization of uptake activity for protein expression level, of clear importance for comparing Vmax values. This finding is consistent with data generated recently in human and rat hepatocytes showing that differences in Vmax are functionally more important than differences in Km for determining species differences in taurocholate uptake (Shitara et al., 2003). However, this trend is in disagreement with several previous studies suggesting that Ntcp had a higher apparent Km for taurocholate than NTCP. The apparent Km value determined in the present study for human NTCP-mediated taurocholate transport was 2.1 ± 1.4 µM and is within the range of reported literature values of 1.6 to 7.9 µM (Hagenbuch and Meier, 1994; Kim et al., 1999; Shitara et al., 2003; Ho et al., 2004). In contrast, our rat Ntcp apparent Km of 2.6 ± 1.6 µM was lower than published values for Ntcp [e.g., 10 ± 6.0 and 30 ± 17 (mean ± S.D. calculated from reported S.E. assuming n = 3)] (Hagenbuch et al., 1991; Torchia et al., 1996; Schroeder et al., 1998; Sun et al., 2001; Hata et al., 2003). To our knowledge the present study in HEK293 cells is the first report in which side-by-side kinetic parameters for taurocholate uptake have been determined for NTCP and Ntcp.
To characterize regions of NTCP and Ntcp that are important for species differences in taurocholate uptake and bosentan inhibition of taurocholate transport, two chimeric Ntcp/NTCP molecules were generated. These proteins were expressed, and cell surface biotinylation experiments confirmed that they were localized properly to the plasma membrane of HEK293 cells. Kinetic analysis of taurocholate transport by chimeric proteins provided evidence that the carboxyl halves of NTCP and Ntcp are important for the differences in Vmax. Results from the characterization of bosentan inhibition of NTCP, Ntcp, NTCP1–140/Ntcp141–362, and Ntcp1–140/NTCP141–349 were more complicated because of the different modes of inhibition.
The mode of bosentan inhibition of taurocholate uptake by NTCP and NTCP1–140/Ntcp141–362 was found to be competitive with apparent Ki values of 18 and 1.7 µM, respectively. These data suggested that the first 140 amino acids of NTCP were important for competitive inhibition by bosentan. In contrast, bosentan was a noncompetitive inhibitor of Ntcp and a mixed competitive and noncompetitive inhibitor of Ntcp1–140/NTCP141–349, which is not consistent with the first 140 amino acids being important for competitive inhibition. The apparent Ki values demonstrated that, as for Ntcp, bosentan was a more potent inhibitor of NTCP1–140/Ntcp141–362 than NTCP, suggesting that the carboxyl portion of Ntcp was important for the species difference in bosentan inhibitory potency. However, this theory was not confirmed using the Ntcp1–140/NTCP141–349 chimera, which had an apparent Ki value of 7 µM, which falls midway between the Ki values for NTCP and Ntcp. Thus, the mechanism of bosentan inhibition of NTCP, Ntcp, NTCP1–140/Ntcp141–362, and Ntcp1–140/NTCP141–349 was found to be complex. Random chimeragenesis and site-directed mutagenesis are currently underway to further define the regions of rat Ntcp and human NTCP important for function and interaction with bosentan and other drugs of hepatotoxic relevance.
NTCP and BSEP are known to be polymorphic, and genetic mutations that alter the interaction of bosentan with either of these proteins could shift the balance of bile acid uptake and efflux (Ho et al., 2004; Meier et al., 2006). In addition, bile acids are also substrates for multidrug resistance-associated proteins (MRP) 3/ABCC3 and MRP4/ABCC4 (Hirohashi et al., 1999; Rius et al., 2003; Zelcer et al., 2003), efflux pumps present on the basolateral surface of hepatocytes; polymorphisms in these genes (Saito et al., 2002; Lang et al., 2004; Lee et al., 2004) also could contribute to interindividual susceptibility to toxicity. We speculate that such polymorphisms could be related to the interindividual differences in susceptibility to bosentan-induced hepatotoxicity observed clinically.
Overall, our observation that Ntcp is more sensitive than NTCP to inhibition by bosentan may represent a novel mechanism to account for the apparent species differences in bosentan-induced hepatotoxicity and should be considered in other cases of drug-induced liver injury.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Dr. Paul B. Watkins is a paid consultant for Actelion, the manufacturer of bosentan. Dr. Kim L. R. Brouwer is a cofounder and Chair of the Scientific Advisory Board for Qualyst, Inc., which has exclusively licensed the sandwich-cultured hepatocyte technology for quantification of biliary excretion (B-CLEAR). None of the other authors has a conflict of interest.
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
ABBREVIATIONS: ET, endothelin; BSEP/ABCB11, human bile salt export pump; Ntcp/Slc10a1, rat Na+-dependent taurocholate cotransporting polypeptide; NTCP/SLC10A1, human Na+-dependent taurocholate cotransporting polypeptide; DMEM, Dulbecco's modified Eagle's medium; HBSS, Hanks' balanced salt solution; HEK, human embryonic kidney; SC, sandwich-cultured; PCR, polymerase chain reaction; PBS, phosphate-buffered saline.
1 Current affiliation: Department of Physiology, University of Alberta, Edmonton, Alberta, Canada. 
2 Current affiliation: Division of Clinical Pharmacology, Department of Medicine, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.
Address correspondence to: Dr. Kim L. R. Brouwer, CB#7360, Kerr Hall, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599-7360. E-mail: kbrouwer{at}unc.edu
|
References |
|---|
|
TopAbstractMaterials and MethodsResultsDiscussionReferences |
|---|
Alvaro D, Cantafora A, Attili AF, Ginanni Corradini S, De Luca C, Minervini G, Di Biase A, and Angelico M (1986) Relationships between bile salts hydrophilicity and phospholipid composition in bile of various animal species. Comp Biochem Physiol B 83: 551-554.[CrossRef][Medline]
Annaert PP and Brouwer KLR (2005) Assessment of drug interactions in hepatobiliary transport using rhodamine 123 in sandwich-cultured rat hepatocytes. Drug Metab Dispos 33: 388-394.
Banerjee A and Swaan PW (2006) Membrane topology of human ASBT (SLC10A2) determined by dual label epitope insertion scanning mutagenesis: new evidence for seven transmembrane domains. Biochemistry 45: 943-953.[CrossRef][Medline]
Cohen H, Chahine C, Hui A, and Mukherji R (2004) Bosentan therapy for pulmonary arterial hypertension. Am J Health Syst Pharm 61: 1107-1119.
Coleman R, Iqbal S, Godfrey PP, and Billington D (1979) Membranes and bile formation: composition of several mammalian biles and their membrane-damaging properties. Biochem J 178: 201-208.[Medline]
Crocenzi FA, Sisti A, Pellegrino JM, and Roma MG (1997) Role of bile salts in colchicine-induced hepatotoxicity: implications for hepatocellular integrity and function. Toxicology 121: 127-142.[CrossRef][Medline]
Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, and Meier PJ (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69: 223-231.[CrossRef][Medline]
Geyer J, Wilke T, and Petzinger E (2006) The solute carrier family SLC10: more than a family of bile acid transporters regarding function and phylogenetic relationships. Naunyn Schmiedebergs Arch Pharmacol 372: 413-431.[CrossRef][Medline]
Ghibellini G, Leslie EM, and Brouwer KLR (2006) Methods to evaluate biliary excretion of drugs in humans: an updated review. Mol Pharm 3: 198-211.[CrossRef][Medline]
Hagenbuch B and Meier PJ (1994) Molecular cloning, chromosomal localization, and functional characterization of a human liver Na+/bile acid cotransporter. J Clin Invest 93: 1326-1331.[Medline]
Hagenbuch B, Stieger B, Foguet M, Lubbert H, and Meier PJ (1991) Functional expression cloning and characterization of the hepatocyte Na+/bile acid cotransport system. Proc Natl Acad Sci USA 88: 10629-10633.
Hamilton GA, Jolley SL, Gilbert D, Coon DJ, Barros S, and LeCluyse EL (2001) Regulation of cell morphology and cytochrome P450 expression in human hepatocytes by extracellular matrix and cell-cell interactions. Cell Tissue Res 306: 85-99.[CrossRef][Medline]
Hata S, Wang P, Eftychiou N, Ananthanarayanan M, Batta A, Salen G, Pang KS, and Wolkoff AW (2003) Substrate specificities of rat oatp1 and ntcp: implications for hepatic organic anion uptake. Am J Physiol 285: G829-G839.
Hirohashi T, Suzuki H, and Sugiyama Y (1999) Characterization of the transport properties of cloned rat multidrug resistance-associated protein 3 (Mrp3). J Biol Chem 274: 15181-15185.
Ho RH, Leake BF, Roberts RL, Lee W, and Kim RB (2004) Ethnicity-dependent polymorphism in Na+-taurocholate cotransporting polypeptide (SLC10A1) reveals a domain critical for bile acid substrate recognition. J Biol Chem 279: 7213-7222.
Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, and Kim RB (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130: 1793-1806.[CrossRef][Medline]
Hoffmaster KA, Turncliff RZ, LeCluyse EL, Kim RB, Meier PJ, and Brouwer KLR (2004) P-glycoprotein expression, localization, and function in sandwich-cultured primary rat and human hepatocytes: relevance to the hepatobiliary disposition of a model opioid peptide. Pharm Res 21: 1294-1302.[CrossRef][Medline]
Kemp DC, Zamek-Gliszczynski MJ, and Brouwer KLR (2005) Xenobiotics inhibit hepatic uptake and biliary excretion of taurocholate in rat hepatocytes. Toxicol Sci 83: 207-214.
Kim RB, Leake B, Cvetkovic M, Roden MM, Nadeau J, Walubo A, and Wilkinson GR (1999) Modulation by drugs of human hepatic sodium-dependent bile acid transporter (sodium taurocholate cotransporting polypeptide) activity. J Pharmacol Exp Ther 291: 1204-1209.
Lang T, Hitzl M, Burk O, Mornhinweg E, Keil A, Kerb R, Klein K, Zanger UM, Eichelbaum M, and Fromm MF (2004) Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics 14: 155-164.[CrossRef][Medline]
Lee YM, Cui Y, Konig J, Risch A, Jager B, Drings P, Bartsch H, Keppler D, and Nies AT (2004) Identification and functional characterization of the natural variant MRP3-Arg1297His of human multidrug resistance protein 3 (MRP3/ABCC3). Pharmacogenetics 14: 213-223.[CrossRef][Medline]
Liu X, LeCluyse EL, Brouwer KR, Lightfoot RM, Lee JI, and Brouwer KLR (1999) Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. J Pharmacol Exp Ther 289: 1592-1599.
Mano Y, Usui T, and Kamimura H (2007) Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2. Biopharm Drug Dispos 28: 13-18.[CrossRef][Medline]
Mareninova O, Shin JM, Vagin O, Turdikulova S, Hallen S, and Sachs G (2005) Topography of the membrane domain of the liver Na+-dependent bile acid transporter. Biochemistry 44: 13702-13712.[CrossRef][Medline]
Meier Y, Pauli-Magnus C, Zanger UM, Klein K, Schaeffeler E, Nussler AK, Nussler N, Eichelbaum M, Meier PJ, and Stieger B (2006) Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 44: 62-74.[CrossRef][Medline]
Noé J, Stieger B, and Meier PJ (2002) Functional expression of the canalicular bile salt export pump of human liver. Gastroenterology 123: 1659-1666.[CrossRef][Medline]
Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, and Williams DP (2005) The role of metabolic activation in drug-induced hepatotoxicity. Annu Rev Pharmacol Toxicol 45: 177-202.[CrossRef][Medline]
Rius M, Nies AT, Hummel-Eisenbeiss J, Jedlitschky G, and Keppler D (2003) Cotransport of reduced glutathione with bile salts by MRP4 (ABCC4) localized to the basolateral hepatocyte membrane. Hepatology 38: 374-384.[Medline]
Saito S, Iida A, Sekine A, Miura Y, Ogawa C, Kawauchi S, Higuchi S, and Nakamura Y (2002) Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR). J Hum Genet 47: 147-171.[CrossRef][Medline]
Schroeder A, Eckhardt U, Stieger B, Tynes R, Schteingart CD, Hofmann AF, Meier PJ, and Hagenbuch B (1998) Substrate specificity of the rat liver Na+-bile salt cotransporter in Xenopus laevis oocytes and in CHO cells. Am J Physiol 274: G370-G375.[Medline]
Segal ES, Valette C, Oster L, Bouley L, Edfjall C, Herrmann P, Raineri M, Kempff M, Beacham S, and van Lierop C (2005) Risk management strategies in the postmarketing period: safety experience with the US and European bosentan surveillance programmes. Drug Saf 28: 971-980.[CrossRef][Medline]
Shitara Y, Li AP, Kato Y, Lu C, Ito K, Itoh T, and Sugiyama Y (2003) Function of uptake transporters for taurocholate and estradiol 17-D-glucuronide in cryopreserved human hepatocytes. Drug Metab Pharmacokinet 18: 33-41.[CrossRef][Medline]
Sitbon O, McLaughlin VV, Badesch DB, Barst RJ, Black C, Galie N, Humbert M, Rainisio M, Rubin LJ, and Simonneau G (2005) Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol. Thorax 60: 1025-1030.
Sokol RJ, McKim JM Jr, Goff MC, Ruyle SZ, Devereaux MW, Han D, Packer L, and Everson G (1998) Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat. Gastroenterology 114: 164-174.[CrossRef][Medline]
Stieger B, Fattinger K, Madon J, Kullak-Ublick GA, and Meier PJ (2000) Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. Gastroenterology 118: 422-430.[CrossRef][Medline]
Sun AQ, Arrese MA, Zeng L, Swaby I, Zhou MM, and Suchy FJ (2001) The rat liver Na+/bile acid cotransporter: importance of the cytoplasmic tail to function and plasma membrane targeting. J Biol Chem 276: 6825-6833.
Tirona RG, Leake BF, Wolkoff AW, and Kim RB (2003) Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther 304: 223-228.
Torchia EC, Shapiro RJ, and Agellon LB (1996) Reconstitution of bile acid transport in the rat hepatoma McArdle RH-7777 cell line. Hepatology 24: 206-211.[CrossRef]
Weber C, Schmitt R, Birnboeck H, Hopfgartner G, Eggers H, Meyer J, van Marle S, Viischer HW, and Jonkman JH (1999) Multiple-dose pharmacokinetics, safety, and tolerability of bosentan, an endothelin receptor antagonist, in healthy male volunteers. J Clin Pharmacol 39: 703-714.[Abstract]
Williams MH, Das C, Handler CE, Akram MR, Davar J, Denton CP, Smith CJ, Black CM, and Coghlan JG (2006) Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 92: 926-932.
Zelcer N, Saeki T, Bot I, Kuil A, and Borst P (2003) Transport of bile acids in multidrug-resistance-protein 3-overexpressing cells co-transfected with the ileal Na+-dependent bile-acid transporter. Biochem J 369: 23-30.[CrossRef][Medline]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|
 |
 |
 |
) or Ca2+-free (cells alone, 
) buffer. Bars represent the means ± S.D. of three experiments (hepatocytes were from human livers 1–3 described in 
) at 37°C in the presence of increasing concentrations of bosentan. Na+-dependent uptake was determined by subtracting [3H]taurocholate uptake in the absence of Na+ from uptake in the presence of Na+. Symbols represent means ± S.D. of triplicate determinations obtained in four (rat) or two (human) independent experiments (human hepatocytes were from livers Hu274 and Hu299 described in 
) or left untransfected (
) and suspended at 4 x 106 cells/ml in HBSS, and taurocholate uptake was measured at 37°C with gentle shaking, as described under Materials and Methods.A,[3H]taurocholate (1 µM; 60 nCi) uptake was measured at the indicated time points. B, [3H]taurocholate transport by transfected HEK293 cells was measured at various taurocholate concentrations (0.6–30 µM; 60–120 nCi) for 90 s at 37°C. Symbols represent the means ± S.D. of triplicate determinations in a single experiment. Similar results were obtained in at least two additional experiments. Activity was normalized to the expression level of each protein relative to NTCP, as determined by immunoblot analysis.
, 40 µM). B, Ntcp transfected HEK293 cells with bosentan (